According to Cushman & Wakefield, Cogentix Medical signed a ten-year lease for a 24,400 s/f, single-story, clean manufacturing facility at 135 Flanders Rd. Cushman & Wakefield executive vice president J.R. McDonald, director Matt Morgan and associate Tyler McGrail represented the tenant, Cogentix Medical, and brokered the transaction.
Cogentix Medical is scheduled to begin occupancy in August. The landlord was represented by CBRE's Bob McGuire and Alison Powers.
135 Flanders Rd. is situated within Flanders Park, a four-building industrial park comprising 105,500 s/f of office and R&D space. The property is located off I-495 and close to I-90.
Cogentix Medical, a global medical device company, will use the property for the manufacturing of its EndoSheath technology, a state-of-the-art protective microbial barrier used for endoscopies. Formed by the March merger between Minnetonka-based Uroplasty and New York-based Vision-Sciences medical device manufacturers, Cogentix Medical will relocate from its current facility based in Natick, Mass.